PTPN22-IN-3
PTPN22-IN-3 is a potent, selective, and orally active inhibitor of PTPN22 with an IC50 of 0.49 μM and a Ki of 0.28 μM. PTPN22-IN-3 exhibits over 14-fold selectivity against a broad panel of PTPs and shows no significant inhibition against SRC/CSK kinases or IDO1/Arginase metalloenzymes. PTPN22-IN-3 enhances TCR signaling, increases IL-2 expression and secretion, and promotes mouse splenic T cell proliferation. In immune-competent C57BL/6J mice, PTPN22-IN-3 suppresses MC38 syngeneic tumor growth and synergizes with Pembrolizumab (anti-PD-1) (HY-P9902A) therapy. PTPN22-IN-3 can be used for the study of colorectal cancer and other solid tumors responsive to T cell-mediated anti-tumor immunity.
For research use only. We do not sell to patients.
- Formula: C28H25N3O6
- Molecular Weight:499.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-2 |
PTPN22-IN-3 (0-25 μM; 3-60 min) shows over 14-fold selectivity for PTPN22 over SHP-2 (IC50 = 7.11 μM), over 47-fold selectivity over PTP1B (IC50 = 23.43 μM), and over 51-fold selectivity over TCPTP (IC50 > 25 μM), shows no inhibition against PTP-MEG2, STEP, PTP-PEST, PTPα, PTPε, PTPγ, PPK, Laforin, CDC14A, or CD45 at concentrations up to 25 μM[1].
PTPN22-IN-3 (1-10 μM; 30 min) exhibits no detectable inhibition against kinases SRC or CSK at concentrations up to 10 μM, and shows no inhibitory activity against metalloenzymes IDO1 or Arginase at 5 μM[1].
PTPN22-IN-3 (10 μM; 1 h) enhances anti-CD3-induced phosphorylation of LCK (Y394) and ERK1/2 (T202/Y204) in Jurkat T cells[1].
PTPN22-IN-3 (1-10 μM; 1 h) increases LCK and ERK1/2 phosphorylation levels in Jurkat T cells in a dose-dependent manner[1].
PTPN22-IN-3 (10 μM; 1 h) enhances anti-CD28-mediated IL-2 expression and IL-2 secretion in Jurkat T cells[1].
PTPN22-IN-3 (10 μM; 24 h) promotes mouse splenic T cell proliferation[1].
PTPN22-IN-3 (up to 30 μM; 24 h) shows no observable cytotoxicity in HEK293 cells[1].
PTPN22-IN-3 (up to 10 μM; 24 h) does not impair the growth of MC38 tumor cells or murine splenic T cells in CCK8 cytotoxicity assays[1].
PTPN22-IN-3 (0-100 μM; 60 min) shows an IC50 of 0.53 μM against PTPN22 in the presence of Triton X-100 in the assay buffer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat T cells
-
Concentration:10 μM
-
Incubation Time:1 h
-
Result:Enhanced anti-CD3-induced phosphorylation of LCK (Y394) and ERK1/2 (T202/Y204).
Enhanced anti-CD28-mediated IL-2 expression.
-
Cell Line:Jurkat T cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:1 h
-
Result:Increased LCK and ERK1/2 phosphorylation in a dose-dependent manner.
-
Cell Line:Mouse splenic T cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Promoted mouse splenic T cell proliferation.
-
Cell Line:HEK293 cells
-
Concentration:Up to 30 μM
-
Incubation Time:24 h
-
Result:Showed no observable cytotoxicity at up to 30 μM.
-
Cell Line:MC38 cells, mouse splenic T cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:24 h
-
Result:Did not impair the growth of MC38 tumor cells or murine splenic T cells.
PTPN22-IN-3 (10 mg/kg; i.p.; once daily for 2 weeks) significantly inhibits MC38 tumor growth by approximately 53% in immune-competent C57BL/6J mice[1].
PTPN22-IN-3 (10 mg/kg; i.p.; once daily for ten consecutive days) shows no efficacy against MC38 tumor growth in immune-deficient NRG mice[1].
PTPN22-IN-3 (10 mg/kg; i.p.; twice daily for five consecutive days per week for 2 weeks) synergizes with Anti-Mouse PD-1 Antibody (RMP1-14, anti-PD-1) (HY-P99144) in MC38 tumor-bearing C57BL/6J mice[1].
PTPN22-IN-3 (10 mg/kg; i.p.; once daily for 2 weeks) in MC38 tumor-bearing C57BL/6J mice increases CD45+ immune cell infiltration, CD3+ T cell infiltration, CD4+ and CD8+ T cell populations, activates CD8+ T cells and NK cells (increased CD69 expression), and induces higher PD-1 expression on CD8+ T cells in the tumor microenvironment, consistent with a phenotypic shift associated with T cell activation[1].
PTPN22-IN-3 (up to 100 mg/kg; i.p.; once daily for 5 days) shows no signs of toxicity in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immune-competent C57BL/6J mice (12 weeks old, both sexes)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice daily for five consecutive days per week for 2 weeks
-
Result:Reduced MC38 tumor volume by approximately 83%.
-
Animal Model:Immune-competent C57BL/6J mice (12 weeks old, both sexes)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once daily for 2 weeks
-
Result:Inhibited MC38 tumor growth by approximately 53%.
-
Animal Model:Immune-deficient NRG mice (12 weeks old, females)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once daily for ten consecutive days
-
Result:Showed no efficacy against MC38 tumor growth.
-
Animal Model:MC38 tumor-bearing C57BL/6J mice (12 weeks old, both sexes)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice daily for five consecutive days per week for 2 weeks
-
Result:Synergized with anti-PD-1 antibody.
-
Animal Model:MC38 tumor-bearing C57BL/6J mice (12 weeks old, both sexes)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; once daily for 2 weeks
-
Result:Increased CD45+ immune cell infiltration, CD3+ T cell infiltration, CD4+ and CD8+ T cell populations, activates CD8+ T cells and NK cells (increased CD69 expression), and induces higher PD-1 expression on CD8+ T cells in the tumor microenvironment, consistent with a phenotypic shift associated with T cell activation.
Chemical Information
-
Molecular Weight 499.51
-
Formula C28H25N3O6
-
SMILES
O=C1C(C(O)=O)=CNC2=CC=C(C=C21)NC([C@@H](NC(C3=C(C=C(C=C3)C4=CC=C(C=C4)CC)O)=O)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PTPN22-IN-3 Related Classifications
HY-184931 Related Classifications
Powered by Bioz